Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Adding daratumumab to existing multiple myeloma regimen of lenalidomide, bortezomib and dexamethasone

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 442

Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA

Prof Peter Voorhees speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston about the GRIFFIN Phase II study.

He explains that the study is adding daratumumab to the existing regimen of lenalidomide, bortezomib and dexamethasone for transplant-eligible newly diagnosed multiple myeloma patients.

Prof Voorhees says the study has found that adding daratumumab to this combination is not only safe, but improves depth of response - but it is too early to say how this might translate into improvements in progression-free survival.


Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation